MANIFESTATION OF THE PARTICULARITIES OF THE USAGE FEATURES OF MONOCLONAL ANTIBODIES IN VARIOUS PHARMACOTHERAPEUTIC APPLICATIONS

MANIFESTATION OF THE PARTICULARITIES OF THE USAGE FEATURES OF MONOCLONAL ANTIBODIES IN VARIOUS PHARMACOTHERAPEUTIC APPLICATIONS

Authors

DOI:

https://doi.org/10.52340/jecm.2023.04.14

Keywords:

Usage, features, monoclonal antibodies, clinical, therapeutic, applications

Abstract

Monoclonal antibodies have been used for the treatment of various severe diseases, such as rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, cancer infections among others. They have immunomodulatory effects, are prepared against specific cytokines, inhibit specific enzymes or signaling molecules. Monoclonal antibodies are generally well tolerated, but those that suppress the immune system may reactivate latent infections, such as tuberculosis or hepatitis B. Most monoclonal antibodies in oncology are administered in body-size-based dosing schedules. Monoclonal antibody-based immunotherapy is now considered to be a main component of cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies possess a diverse set of clinically relevant mechanisms of action. In addition, antibodies can directly target tumor cells while simultaneously promoting the induction of long-lasting anti-tumor immune responses. The multifaceted properties of antibodies as a therapeutic platform have led to the development of new cancer treatment strategies that will have major impacts on cancer care.

Downloads

Download data is not yet available.

References

Koike H, Kadoya M, Kaida KI, Ikeda S, Kawagashira Y, Iijima M, et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry. 2017;88(6):465-73.

Dalakas MC. IgG4-mediated neurologic autoimmunities: Understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1116.

Martin-Aguilar L, Lleixa C, Pascual-Goni E, Caballero-Avila et al. Clinical and laboratory features in anti-NF155 autoimmune nodopathy. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e1098.

Scheibe F, Ostendorf L, Pruss H, Radbruch H, Aschman T, Hofmann S, et al. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol. 2022; 29(6):1847-1854.

Beadon K, Guimaraes-Costa R, Leger JM. Multifocal motor neuropathy. Curr Opin Neurol. 2018;31(5):559-64.

Nobile-Orazio E, Giannotta C, Musset L, Messina P, Leger JM. Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2014;85(7):754-8.

Sudo M, Miyaji K, Spath PJ, Morita-Matsumoto K, Yamaguchi Y, Yuki N. Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies. Int Immunopharmacol. 2016; 40:11–5.

Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365:725-733.

Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119:2709-2720.

Briani C, Visentin A. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies. Neurotherapeutics. 2022 Apr; 19(3):874-884.

Cortese A, Lombardi R, Briani C, Callegari I, Benedetti L, Manganelli F, et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2019; 7(1):e639.

Stengel H, Vural A, Brunder AM, Heinius A, Appeltshauser L, et al. Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy. Neurol Neuroimmunol Neuroinflamm. 2019; 6(5):e603.

Fels M, Fisse AL, Schwake C, Motte J, et al. Report of a fulminant anti-pan-neurofascin-associated neuropathy responsive to rituximab and bortezomib. J Peripher Nerv Syst. 2021; 26(4):475-480.

Pascual-Goni E, Fehmi J, Lleixa C, et al. Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2021; 144(4):1183-96.

Querol L, Devaux J, Rojas-Garcia R, Illa I. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol. 2017;13(9):533-47.

Doppler K, Appeltshauser L, Wilhelmi K, Villmann C, Dib-Hajj SD, et al. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neutosurg Psychiatry. 2015; 86(7):720-8.

Downloads

Published

2023-11-26

How to Cite

SULASHVILI, N., GORGASLIDZE, N., GABUNIA, L., GIORGOBIANI, M., & RATIANI, L. (2023). MANIFESTATION OF THE PARTICULARITIES OF THE USAGE FEATURES OF MONOCLONAL ANTIBODIES IN VARIOUS PHARMACOTHERAPEUTIC APPLICATIONS. Experimental and Clinical Medicine Georgia, (4), 52–57. https://doi.org/10.52340/jecm.2023.04.14

Issue

Section

Articles

Most read articles by the same author(s)

1 2 > >> 

Similar Articles

<< < 13 14 15 16 17 18 

You may also start an advanced similarity search for this article.

Loading...